Phimelanotide - Clinuvel Pharmaceuticals
Alternative Names: Phimelanotide; VLRX002Latest Information Update: 28 Feb 2024
At a glance
- Originator University of Arizona
- Developer Clinuvel Pharmaceuticals
- Class Hormonal replacements; Melanocortins; Melanocyte-stimulating hormones; Peptide hormones; Skin disorder therapies
- Mechanism of Action Melanocortin type 1 receptor modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Vitiligo
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for research development in Vitiligo in Singapore
- 01 Jan 2020 Early research in Vitiligo in Singapore before January 2020 (Clinuvel Pharmaceuticals pipeline, January 2020)